Get 20% Free Customization In This Report

Buy this report from - $3456

Global Duchenne Muscular Dystrophy Therapeutics Market by Type (Pain Management Drugs and Corticosteroids) and by End-User (Hospitals, Clinics, and Home Care Settings) - Opportunity Analysis and Industry Forecast, 2017-2023

Pharmaceuticals	LI_184102	Pages: NA	Jun 2018 \| 524 Views
Author's : NA	Tables: NA	Charts: NA	Formats*:

Duchenne muscular dystrophy (DMD) therapeutics helps treat genetic disorder caused due to absence of dystrophin, a protein in the body. The symptoms of the disease include weakness in the muscles of the hips, pelvic area, thighs, and shoulders, and later in the muscles of arms, legs, and trunk.

Factors such as, increase in incidences of Duchenne muscular dystrophy and introduction of specific guidance for development for Duchenne muscular dystrophy drugs by FDA drive the market growth. However, low rate of treatment due to delayed diagnosis and prediction hinder the market growth. Moreover, fast track approval of these drugs by FDA and untapped growth opportunities in the emerging economies of Asia-Pacific and LAMEA are expected to fuel the market growth during the forecast period.

The global Duchenne muscular dystrophy therapeutics market is segmented on the basis of type, end user, and region. On the basis of type, it is bifurcated into pain management drugs and corticosteroids. Corticosteroids are further sub-segmented into prednisolone, prednisone, and deflazacort. On the basis of end-user, it is divided into hospitals, clinics, and home care settings. By geography, it is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA).

Key players in the market include Bristol-Myers Squibb Company, FibroGen, Inc., ITALFARMACO S.p.A., Marathon Pharmaceuticals, LLC, NS Pharma, Inc, PTC Therapeutics, Inc., Pfizer Inc., ReveraGen BioPharma, Inc., Santhera Pharmaceuticals, and Sarepta Therapeutics, Inc.

Key Benefits

The study provides an in-depth analysis of the market with current trends and future estimations to elucidate the imminent investment pockets.
It offers a quantitative analysis from 2016 to 2023, which is expected to enable the stakeholders to capitalize on prevailing market opportunities.
Extensive analysis by product helps understand various therapeutics used for Duchenne dystrophy.
Comprehensive analysis of all geographical regions is provided, which helps determine the prevailing opportunities.
Key players are profiled and their strategies are analyzed thoroughly, which elucidates the competitive outlook of the global market.

Duchenne Muscular Dystrophy Therapeutics Market Key Segments:

By Type

Pain Management Drugs
Corticosteroids
Prednisolone
Prednisone
Deflazacort

By End User

Hospitals
Clinics
Home Care Settings

By Region

North America
- U.S.
- Canada
- Mexico
Europe
- Germany
- UK
- France
- Italy
- Spain
- Rest of Europe
Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
LAMEA
- Brazil
- South Africa
- Saudi Arabia
- Rest of LAMEA

Chapter: 1 INTRODUCTION

1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models

Chapter: 2 EXECUTIVE SUMMARY

2.1. CXO PERSPECTIVE

Chapter: 3 MARKET OVERVIEW

3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS

3.2.1. Top investment pockets
3.2.2. Top winning strategies

3.3. MARKET SHARE ANALYSIS, 2016
3.4. PORTER’S FIVE FORCES ANALYSIS

3.4.1. MARKET DYNAMICS
3.4.2. Drivers
3.4.3. Restraints
3.4.4. Opportunities

Chapter: 4 GLOBAL DUCHENNE MUSCULAR DYSTROPHY THERAPEUTICS MARKET, BY TREATMENT TYPE

4.1. OVERVIEW

4.1.1. Market size and forecast

4.2. PAIN MANAGEMENT DRUDS

4.2.1. Key market trends
4.2.2. Growth factors and opportunities
4.2.3. Market size and forecast

4.3. CORTECOSTEROIDS

4.3.1. Key market trends
4.3.2. Growth factors and opportunities
4.3.3. Market size and forecast

4.3.3.1. Prednisolone

4.3.3.1.1. Market Size and Forecast

4.3.3.2. Prednisone

4.3.3.2.1. Market Size and Forecast

4.3.3.3. Deflazacort

4.3.3.3.1. Market Size and Forecast

Chapter: 5 GLOBAL DUCHENNE MUSCULAR DYSTROPHY THERAPEUTICS MARKET, BY END USER

5.1. OVERVIEW

5.1.1. Market size and forecast

5.2. HOSPITALS

5.2.1. Market size and forecast

5.3. CLINICS

5.3.1. Market size and forecast

5.4. HOME CARE SETTINGS

5.4.1. Market size and forecast

Chapter: 6 GLOBAL DUCHENNE MUSCULAR DYSTROPHY THERAPEUTICS MARKET, BY REGION

6.1. OVERVIEW
6.2. NORTH AMERICA

6.2.1. Key market trends
6.2.2. Key growth factors and opportunities
6.2.3. Market size and forecast

6.2.3.1. U.S. market size and forecast
6.2.3.2. Canada market size and forecast
6.2.3.3. Mexico market size and forecast

6.2.4. North America Duchenne Muscular Dystrophy Therapeutics Market, by Treatment Type
6.2.5. North America Duchenne Muscular Dystrophy Therapeutics Market, by End User

6.3. EUROPE

6.3.1. Key market trends
6.3.2. Key growth factors and opportunities
6.3.3. Market size and forecast

6.3.3.1. Germany market size and forecast
6.3.3.2. France market size and forecast
6.3.3.3. UK market size and forecast
6.3.3.4. Italy market size and forecast
6.3.3.5. Spain market size and forecast
6.3.3.6. Rest of Europe market size and forecast

6.3.4. Europe Duchenne Muscular Dystrophy Therapeutics Market, by Treatment Type
6.3.5. Europe Duchenne Muscular Dystrophy Therapeutics Market, by End User

6.4. ASIA-PACIFIC

6.4.1. Key market trends
6.4.2. Key growth factors and opportunities
6.4.3. Market size and forecast

6.4.3.1. Japan market size and forecast
6.4.3.2. China market size and forecast
6.4.3.3. Australia market size and forecast
6.4.3.4. India market size and forecast
6.4.3.5. South Korea market size and forecast
6.4.3.6. Rest of Asia-Pacific market size and forecast

6.4.4. Asia-Pacific Duchenne Muscular Dystrophy Therapeutics Market, by Treatment Type
6.4.5. Asia-Pacific Duchenne Muscular Dystrophy Therapeutics Market, by End User

6.5. LAMEA

6.5.1. Key market trends
6.5.2. Key growth factors and opportunities
6.5.3. Market size and forecast

6.5.3.1. Brazil market size and forecast
6.5.3.2. Saudi Arabia market size and forecast
6.5.3.3. South Africa market size and forecast
6.5.3.4. Rest of LAMEA market size and forecast

6.5.4. LAMEA Duchenne Muscular Dystrophy Therapeutics Market, by Treatment Type
6.5.5. LAMEA Duchenne Muscular Dystrophy Therapeutics Market, by End User

Chapter: 7 COMPANY PROFILES

7.1. BRISTOL-MYERS SQUIBB COMPANY

7.1.1. Operating business segments
7.1.2. Business performance
7.1.3. Key strategic moves and developments

7.2. FIBROGEN, INC.

7.2.1. Operating business segments
7.2.2. Business performance
7.2.3. Key strategic moves and developments

7.3. ITALFARMACO S.P.A.

7.3.1. Operating business segments
7.3.2. Business performance
7.3.3. Key strategic moves and developments

7.4. MARATHON PHARMACEUTICALS, LLC

7.4.1. Operating business segments
7.4.2. Business performance
7.4.3. Key strategic moves and developments

7.5. NS PHARMA, INC

7.5.1. Operating business segments
7.5.2. Business performance
7.5.3. Key strategic moves and developments

7.6. PTC THERAPEUTICS, INC.

7.6.1. Operating business segments
7.6.2. Business performance
7.6.3. Key strategic moves and developments

7.7. PFIZER INC.

7.7.1. Operating business segments
7.7.2. Business performance
7.7.3. Key strategic moves and developments

7.8. REVERAGEN BIOPHARMA, INC.

7.8.1. Operating business segments
7.8.2. Business performance
7.8.3. Key strategic moves and developments

7.9. SANTHERA PHARMACEUTICALS

7.9.1. Operating business segments
7.9.2. Business performance
7.9.3. Key strategic moves and developments

7.10. SAREPTA THERAPEUTICS, INC

7.10.1. Operating business segments
7.10.2. Business performance
7.10.3. Key strategic moves and developments

With collective industry experience of about 200 years of its analysts and experts, Allied Market Research (AMR) encompasses most infallible research methodology for its market intelligence and industry analysis. We do not only engrave the deepest levels of markets but also sneak through its slimmest details for the purpose of our market estimates and forecasts. Our approach helps in building greater market consensus view for size, shape and industry trends within each industry segment. We carefully factor in industry trends and real developments for identifying key growth factors and future course of the market. Our research proceeds are the resultant of high quality data, expert views and analysis and high value independent opinions. Our research process is designed to deliver balanced view of the global markets and allow stakeholders to make informed decisions.

We offer our clients exhaustive research and analysis based on wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics and regional intelligence. Our in-house industry experts play instrumental role in designing analytic tools and models, tailored to the requirements of particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of our recommendations and advice. With AMR’s calibrated research process and 360` degree data-evaluation methodology, our clients are assured of receiving:

Consistent, valuable, robust and actionable data & analysis that can easily be referenced for strategic business planning
Technologically sophisticated and reliable insights through well audited and veracious research methodology
Sovereign research proceeds that present a tangible depiction of marketplace

With a strong methodology we are, therefore, confident that our research and analysis are most reliable and guarantees sound business planning.

Secondary research
We refer a broad array of industry sources for our secondary, which typically include; however, not limited to: Company SEC filings, annual reports, company websites, broker & financial reports and investor presentations for competitive scenario and shape of the industry

Patent and regulatory databases for understanding of technical & legal developments
Scientific and technical writings for product information and related preemptions
Regional government and statistical databases for macro analysis
Authentic new articles, web-casts and other related releases for market evaluation
Internal and external proprietary databases, key market indicators and relevant press releases for market estimates and forecast

Primary research
Our primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks and face-to-face interactions. We are also in professional corporate relations with various companies that allow us greater flexibility for reaching out industry participants and commentators for interviews and discussions, fulfilling following functions:

Validates and improves the data quality and strengthens research proceeds
Further develops analyst team’s market understanding and expertise
Supplies authentic information about market size, share, growth and forecasts

Our primary research interview and discussion panels are typically composed of most experienced industry members. These participants include; however, not limited to:

Chief executives and VPs of leading corporations specific to industry
Product and sales managers or country heads; channel partners and top level distributors; banking, investments and valuation experts Key opinion leaders (KOLs)

Analyst tools and models
AMR has developed set of analyst tools and data models to supplement and expedite the analysis process. Corresponding to markets, where there is significant lack of information and estimates, AMR’s team of experts and analyst develop specific analyst tools and industry models to translate qualitative and quantitative industry indicators into exact industry estimates. These models also allow analysts to examine the prospects and opportunities prevailing in the market to accurately forecast the course of the market.